David Risinger

David Risinger Recent News

Large Option Trader Makes Aggressive Bearish Play On Teva
Large Option Trader Makes Aggressive Bearish Play On Teva
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns
Morgan Stanley Downgrades Teva, Endo On Drug Pricing And Litigation Concerns
Morgan Stanley Loses Confidence In Allergan's Pipeline Optionality
Morgan Stanley Loses Confidence In Allergan's Pipeline Optionality
Morgan Stanley Turns Bullish On Bausch Health: 'We Expect 2018 To Be The Last Year Of Declining Financials'
Morgan Stanley Turns Bullish On Bausch Health: 'We Expect 2018 To Be The Last Year Of Declining Financials'
Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade
Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade
3 Headwinds Hindering Mylan
3 Headwinds Hindering Mylan
Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target
Morgan Stanley Downgrades Jazz Pharmaceuticals As Stock Approaches Price Target
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
One Up, One Down: Morgan Stanley Flips Merck, Bristol-Myers Ratings
Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target
Zoetis Downgraded As Valuation Approaches Morgan Stanley's Price Target
Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot
Morgan Stanley: As Generic Competitors Falter, Mylan Is Worth A Shot
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
Morgan Stanley Targets New All-Time High For Bristol-Myers, Upgrades To Overweight
Analyst: Zoetis Deserves To Trade At A Premium
Analyst: Zoetis Deserves To Trade At A Premium
The Bull Thesis For Merck Is Evaporating
The Bull Thesis For Merck Is Evaporating
Pfizer Should Outperform, Morgan Stanley Upgrades
Pfizer Should Outperform, Morgan Stanley Upgrades
Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
Mylan Price Target Slashed Even As TLD Drug Receives Tentative Approval
Merck's Leadership Position In Immuno Oncology Is Improving
Merck's Leadership Position In Immuno Oncology Is Improving
Morgan Stanley Cuts Teva's Price Target By 33%
Morgan Stanley Cuts Teva's Price Target By 33%
Morgan Stanley Cuts Valeant's Target To $25, Admits It Got A Couple Things Wrong
Morgan Stanley Cuts Valeant's Target To $25, Admits It Got A Couple Things Wrong
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2025 Benzinga | All Rights Reserved